
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Ocugen, Inc is a biotechnology business with stocks listed in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$0.185 - US$14.59 |
---|---|
50-day moving average | US$5.0276 |
200-day moving average | US$1.5967 |
Target price | US$6.63 |
PE ratio | 0.0762 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-4.8349 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | US$42,620 |
---|---|
Gross profit TTM | US$0 |
Return on assets TTM | -38.66% |
Return on equity TTM | -850.6% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | US$1.6 billion |
TTM: trailing 12 months
There are currently 11.3 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 23.4% down from 14.8 million last month.
There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.
Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 37.8 million). Ocugen's SIR currently stands at 0.3. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 300 shares are currently held short.
However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 70 shares are currently held short) or 0.0723% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.
Find out more about how you can short Ocugen stock.
We're not expecting Ocugen to pay a dividend over the next 12 months.
Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the seven best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.